Close Menu

NEW YORK (GenomeWeb) – Meridian Bioscience reported today that its fiscal third quarter revenues rose 5 percent year over year, driven largely by its newly-acquired Magellan Diagnostics business.

For the three months ended June 30, Meridian posted net revenues of $50.7 million compared to $48.2 million in the year ago quarter, and missing analysts' consensus estimate of $52.9 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.